JIANMIN GROUP(SH:600976) Shang Hai Zheng Quan Bao·2025-10-21 18:40Core Viewpoint - The company reported a decline in revenue and net profit for the year-to-date period, primarily due to changes in its business structure and reduced investment income [3][4]. Financial Performance - Year-to-date revenue decreased by 11.43%, with the pharmaceutical manufacturing segment growing by 19.67% due to increased sales of main and new products, while the pharmaceutical commercial segment saw a decline of 36.91% due to the optimization of business structure [3]. - The net profit attributable to shareholders decreased by 11.16%, mainly due to reduced investment income from associates and non-recurring gains [3]. Non-Recurring Gains and Losses - The report indicates that there are no significant non-recurring gains or losses that have been classified incorrectly [4]. Shareholder Information - There are no changes in the top ten shareholders or any significant movements in share lending activities [6]. Audit Status - The financial statements for the third quarter are unaudited, and the company has not applied new accounting standards for the current reporting period [8].